Related Experiment Video
Updated: Mar 6, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Albuminuria in Rheumatoid Arthritis: Associations With Rheumatoid Arthritis Characteristics and Subclinical
Amanda Sammut1, Steven Shea1, Roger S Blumenthal2
1Columbia University College of Physicians & Surgeons, New York, New York.
Insights
Albuminuria, a marker for cardiovascular disease (CVD), is not associated with subclinical CVD in rheumatoid arthritis (RA) patients. Tumor necrosis factor inhibitors may reduce elevated urine albumin-to-creatinine ratio (uACR) in RA.
Area of Science:
- Rheumatology
- Cardiology
- Nephrology
Background:
- Albuminuria is a recognized indicator of subclinical cardiovascular disease (CVD) in the general population.
- Rheumatoid arthritis (RA) patients exhibit increased atherosclerosis and CVD events, but the role of albuminuria in this population is unclear.
Purpose of the Study:
- To investigate the association between elevated urine albumin-to-creatinine ratio (uACR) and subclinical CVD in patients with RA compared to non-RA controls.
- To explore the relationship between uACR, CVD risk factors, and atherosclerosis measures in RA patients.
Main Methods:
- Cross-sectional comparison of 196 RA patients and 271 non-RA controls.
- Measurement of urine albumin-to-creatinine ratio (uACR) from spot morning collections.
- Assessment of associations with CVD risk factors and atherosclerosis measures (coronary artery calcification, carotid intima-media thickness, carotid plaque).
Main Results:
- Elevated uACR prevalence was similar between RA patients (18%) and controls (17%).
- RA was associated with 57% lower odds of elevated uACR after adjustment (P=0.016).
- Elevated uACR was not associated with atherosclerosis or cardiometabolic risk factors in RA patients. Treatment with tumor necrosis factor inhibitors was associated with lower uACR prevalence (9% vs. 20%, P=0.047).
Conclusions:
- Elevated uACR is not a reliable indicator of subclinical CVD in RA patients.
- The association between uACR and CVD risk factors differs between RA patients and controls.
- Tumor necrosis factor inhibitor use may be linked to a reduced prevalence of elevated uACR in RA.
Objective:
Albuminuria is a marker for subclinical cardiovascular disease (CVD) in the general population. It is uncertain whether this association is present in patients with rheumatoid arthritis (RA), a population with increased atherosclerosis and CVD events.
Methods:
Urine albumin from a spot morning collection was measured, and the urine albumin-to-creatinine ratio (uACR) was calculated for RA patients and a population-based sample of demographically matched non-RA controls. Associations of elevated uACR (≥25 mg/gm for women and ≥17 mg/gm for men) with CVD risk factors and measures of atherosclerosis (coronary artery calcification, ultrasound-determined maximal intima-media thickness of the common carotid artery and internal carotid artery [ICA], and the presence of focal plaque in the ICA) were compared cross-sectionally according to RA status.
Results:
We compared 196 RA patients with 271 non-RA controls. Elevated uACR was found in 18% of the RA patients compared with 17% of the controls (P = 0.89). After adjustment, RA was associated with 57% lower odds of elevated uACR (P = 0.016). Higher serum creatinine levels and hypertension were both strongly and significantly associated with elevated uACR in the control group but not in the RA group (both P for interaction < 0.05). Among RA characteristics, the adjusted prevalence of elevated uACR among those treated with tumor necrosis factor inhibitors was less than half that among those not so treated (9% versus 20%, respectively; P = 0.047).
Conclusion:
There was no association in the RA group of elevated uACR with measures of atherosclerosis or with several key cardiometabolic risk factors, which suggests a lower usefulness of elevated uACR as an indicator of subclinical CVD in RA.
Related Concept Videos
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Chronic Kidney Disease II: Clinical Manifestations
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Nephrotic Syndrome I : Introduction

